BH-002 is under clinical development by Essen Biotech and currently in Phase II for Idiopathic Inflammatory Myopathy (IIM). According to GlobalData, Phase II drugs for Idiopathic Inflammatory Myopathy (IIM) have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BH-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BH-002 overview
BH-002 is under development for the treatment of refractory systemic lupus erythematosus, systemic sclerosis,IGG4-associated diseases, primary Sjogren's syndrome, rheumatoid arthritis, idiopathic inflammatory myopathy (IIM), Interstitial Lung Diseases (diffuse parenchymal lung disease), thrombocytopenia, primary biliary cholangitis (primary biliary cirrhosis). The therapeutic candidate comprises of T cells genetically engineered to express chimeric antigen receptor (CAR) targeting CD19 and BCMA. It is administered through intravenous route.
Essen Biotech overview
Essen Biotech is a research center that offers natural killer cell immuno, MSC stem, bone marrow transplant, proton therapy and CAR-T cell therapy services for the treatment of Alzheimer’s disease, bone tissue injuries and other diseases. The company is headquartered in Gillette, Wyoming, the US.
For a complete picture of BH-002’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
